Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Abciximab: a reappraisal of its use in coronary care.
Valgimigli M, Campo G, Tebaldi M, Carletti R, Arcozzi C, Ferrari R, Percoco G. Valgimigli M, et al. Among authors: arcozzi c. Biologics. 2008 Mar;2(1):29-39. doi: 10.2147/btt.s1374. Biologics. 2008. PMID: 19707425 Free PMC article.
Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial.
Valgimigli M, Bolognese L, Anselmi M, Campo G, Rodriguez AE, de Cesare N, Cohen DJ, Sheiban I, Colangelo S, Pasquetto G, Hamon M, Vranckx P, Ferrario M, Prati F, Agostoni P, Malagutti P, Arcozzi C, Parrinello G, Vassanelli C, Ferrari R, Percoco G. Valgimigli M, et al. Among authors: arcozzi c. Am Heart J. 2007 Jul;154(1):39-45. doi: 10.1016/j.ahj.2007.03.023. Am Heart J. 2007. PMID: 17584549 Clinical Trial.
Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study.
Valgimigli M, Campo G, Arcozzi C, Malagutti P, Carletti R, Ferrari F, Barbieri D, Parrinello G, Percoco G, Ferrari R. Valgimigli M, et al. Among authors: arcozzi c. J Am Coll Cardiol. 2007 Jul 10;50(2):138-45. doi: 10.1016/j.jacc.2007.04.029. Epub 2007 May 22. J Am Coll Cardiol. 2007. PMID: 17616297 Free article. Clinical Trial.
Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events.
Campo G, Valgimigli M, Ferraresi P, Malagutti P, Baroni M, Arcozzi C, Gemmati D, Percoco G, Parrinello G, Ferrari R, Bernardi F. Campo G, et al. Among authors: arcozzi c. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2800-6. doi: 10.1161/01.ATV.0000247249.82030.94. Epub 2006 Sep 28. Arterioscler Thromb Vasc Biol. 2006. PMID: 17008590
Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY).
Valgimigli M, Campo G, Percoco G, Monti M, Ferrari F, Tumscitz C, Zuffi A, Colombo F, Kubbajeh M, Cavazza C, Cangiano E, Tebaldi M, Minarelli M, Arcozzi C, Scalone A, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R. Valgimigli M, et al. Among authors: arcozzi c. Am Heart J. 2010 Nov;160(5):804-11. doi: 10.1016/j.ahj.2010.07.034. Am Heart J. 2010. PMID: 21095265 Clinical Trial.
[Markers of coronary damage. From diagnosis to prognosis].
Valgimigli M, Squasi PA, Gaitani S, Arcozzi C, Martano S, Ferrari R. Valgimigli M, et al. Among authors: arcozzi c. Recenti Prog Med. 2005 Nov;96(11):566-72. Recenti Prog Med. 2005. PMID: 16499168 Review. Italian.
The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction.
Tebaldi M, Arcozzi C, Campo G, Percoco G, Ferrari R, Valgimigli M; STRATEGY Investigators. Tebaldi M, et al. Among authors: arcozzi c. J Am Coll Cardiol. 2009 Nov 10;54(20):1900-1. doi: 10.1016/j.jacc.2009.08.009. J Am Coll Cardiol. 2009. PMID: 19892243 Free article. No abstract available.
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G; PRODIGY Investigators. Valgimigli M, et al. JACC Cardiovasc Interv. 2014 Jan;7(1):20-8. doi: 10.1016/j.jcin.2013.09.008. Epub 2013 Dec 11. JACC Cardiovasc Interv. 2014. PMID: 24332420 Free article. Clinical Trial.
Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R; Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators. Valgimigli M, et al. JAMA. 2008 Apr 16;299(15):1788-99. doi: 10.1001/jama.299.15.joc80026. Epub 2008 Mar 30. JAMA. 2008. PMID: 18375998 Clinical Trial.